"10.1371_journal.pone.0108069","plos one","2014-10-09T00:00:00Z","Tom-Ole L√∏v√•s; Jo C Bruusgaard; Inger √òynebr√•ten; Kristian Gundersen; Bjarne Bogen","Department of Immunology, University of Oslo and Oslo University Hospital, Rikshospitalet, Oslo, Norway; Centre for Immune Regulation, University of Oslo, Oslo, Norway; Department of Biosciences, University of Oslo, Oslo, Norway; Norwegian school of Health Sciences, Kristiania University College, Oslo, Norway; KG Jebsen Centre for research on Influenza Vaccines, University of Oslo, Oslo, Norway","Conceived and designed the experiments: TOL JCB I√ò KG BB. Performed the experiments: TOL JCB I√ò. Analyzed the data: TOL JCB I√ò KG BB. Contributed reagents/materials/analysis tools: TOL JCB I√ò KG BB. Wrote the paper: TOL JCB I√ò KG BB.","Bjarne Bogen is inventor on patent applications filed on the vaccine molecules by the TTO offices of the University of Oslo and Oslo University Hospital, according to institutional rules (US 2004/0253238 A1: Modified Antibody; 61538,186: Vaccibodies targeting to crosspresenting dendritic cells; 10167291.3 - 1222: Homodimeric protein constructs). BB is head of the Scientific panel of the Vaccibody company, and has shares in the company. There are no further patents, products in development or marketed products to declare. This does not alter the authors adherence to all the PLOS ONE policies on sharing data and materials.","2014","10","Tom-Ole L√∏v√•s","TOL√√",5,TRUE,5,3,5,5,TRUE,TRUE,TRUE,1,"3",FALSE
